Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Down-Regulation of Bax and Bak in Immuno-Chemotherapy Resistant Non-Hodgkin’s Lymphoma Cells.

Scott H. Olejniczak, MS, James L. Clements, PhD., Naveen Bangia, PhD., Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman

Blood (2006) 108 (11): 4758.

https://doi.org/10.1182/blood.V108.11.4758.4758

Published: 2006

Journal Articles

Lack of Lipid Raft Domain Reorganization Following Ligation of CD20 Is Associated with Resistance to Rituximab-Induced Complement-Dependent Cytotoxicity.

Scott H. Olejniczak, MS, Francisco J. Hernandez-Ilizaliturri, MD, James L. Clements, PhD, Myron S. Czuczman

Blood (2005) 106 (11): 4818.

https://doi.org/10.1182/blood.V106.11.4818.4818

Published: 2005

Journal Articles

Loss of Expression of the Pro-Apoptotic Bcl-2 Family Proteins Bak and Bax in Rituximab- and Chemotherapy-Resistant Non-Hodgkin’s Lymphoma Cells.

Scott H. Olejniczak, MS, Francisco J. Hernandez-Ilizaliturri, MD, James L. Clements, PhD, Myron S. Czuczman, MD

Blood (2005) 106 (11): 4819.

https://doi.org/10.1182/blood.V106.11.4819.4819

Published: 2005

Journal Articles

Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).

Francisco J. Hernandez-Ilizaliturri, MD, Scott H. Olejniczak, MS, Joy Knight, MS, Myron S. Czuczman, MD

Blood (2005) 106 (11): 1474.

https://doi.org/10.1182/blood.V106.11.1474.1474

Published: 2005

Journal Articles

Acquirement of Rituximab Resistance Is Associated with the Development of Chemotherapy Resistance in B-Cell Lymphoma Cells: Evidence of Shared Pathways of Resistance between Chemotherapeutic Agents and Biological Therapies.

Scott H. Olejniczak, MS, Francisco J. Hernandez, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 2297.

https://doi.org/10.1182/blood.V104.11.2297.2297

Published: 2004

NARROW

Down-Regulation of Bax and Bak in Immuno-Chemotherapy Resistant Non-Hodgkin’s Lymphoma Cells.

Lack of Lipid Raft Domain Reorganization Following Ligation of CD20 Is Associated with Resistance to Rituximab-Induced Complement-Dependent Cytotoxicity.

Loss of Expression of the Pro-Apoptotic Bcl-2 Family Proteins Bak and Bax in Rituximab- and Chemotherapy-Resistant Non-Hodgkin’s Lymphoma Cells.

Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).

Acquirement of Rituximab Resistance Is Associated with the Development of Chemotherapy Resistance in B-Cell Lymphoma Cells: Evidence of Shared Pathways of Resistance between Chemotherapeutic Agents and Biological Therapies.

Email alerts

ASH Publications

American Society of Hematology

Down-Regulation of Bax and Bak in Immuno-Chemotherapy Resistant Non-Hodgkin’s Lymphoma Cells.

Lack of Lipid Raft Domain Reorganization Following Ligation of CD20 Is Associated with Resistance to Rituximab-Induced Complement-Dependent Cytotoxicity.

Loss of Expression of the Pro-Apoptotic Bcl-2 Family Proteins Bak and Bax in Rituximab- and Chemotherapy-Resistant Non-Hodgkin’s Lymphoma Cells.

Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).

Acquirement of Rituximab Resistance Is Associated with the Development of Chemotherapy Resistance in B-Cell Lymphoma Cells: Evidence of Shared Pathways of Resistance between Chemotherapeutic Agents and Biological Therapies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only